Skip to content
value.today

Platelet BioGenesis, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2014
Total raised
$72 M
3 rounds on record
Latest round
$35 M
Oct 2021
First round on record
May 2017
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Platelet BioGenesis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2021$35 MNo. 3$10 to $50 million

Platelet BioGenesis, Inc.: Raise no. 3, Oct 2021

Investors in this round

7 investors had bought by the notice of Nov 4, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sam Rasty · Executive Officer, Director
  • Chidozie Ugwumba · Director
  • Joseph Italiano · Director
  • Mark McDade · Director
  • Philip Reilly · Director
  • Richard Murray · Director
  • Steven Altschuler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sam Rasty, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2021. Read the notice at the SEC.

equitySEC
Jun 2019$26 MNo. 2$10 to $50 million

Platelet BioGenesis, Inc.: Raise no. 2, Jun 2019

Investors in this round

34 investors had bought by the notice of Aug 13, 2019: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sam Rasty · Director, Executive Officer
  • Sven Karlsson · Executive Officer, Director
  • Joseph Italiano · Director
  • Mark McDade · Director
  • Philip Reilly · Director
  • Richard Murray · Director
  • Steve Altschuler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sam Rasty, President. Source: SEC Form D and 1 amendment, newest notice filed Aug 13, 2019. Read the notice at the SEC.

equitySEC
May 2017$10 MNo. 1$10 to $50 million

Platelet BioGenesis, Inc.: Raise no. 1, May 2017

Investors in this round

32 investors had bought by the notice of May 31, 2017: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Thon · Executive Officer, Director
  • Peter Finn · Executive Officer
  • Sven Karlsson · Executive Officer, Director
  • Joseph Italiano · Director
  • Mark McDade · Director
  • Philip Reilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Salaries”

Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed May 31, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Platelet BioGenesis, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2021

That is all the official record says: Platelet BioGenesis, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Platelet BioGenesis, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Platelet BioGenesis, Inc.
NameRoleNamed in
Sam RastyExecutive officerNov 2021
Sven KarlssonExecutive officerAug 2019
Jonathan ThonExecutive officerJun 2019
Peter FinnExecutive officerMay 2017
Chidozie UgwumbaDirectorNov 2021
Joseph ItalianoDirectorNov 2021
Mark McDadeDirectorNov 2021
Philip ReillyDirectorNov 2021
Richard MurrayDirectorNov 2021
Sam RastyDirectorNov 2021
Steven AltschulerDirectorNov 2021
Steve AltschulerDirectorAug 2019
Sven KarlssonDirectorAug 2019
Jonathan ThonDirectorJun 2019